**Table 1. Baseline and procedural characteristics and laboratory data in patients with severe lower extremity arterial diseases**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **No Afib** | | **With Afib** | | | **P** | |
|  | **N = 194** | | **N = 28** | | |  | |
| **Age (years)** | **72.6** | **(11.5)** | | **80.6** | **(9.1)** | | **0.001** |
| **Male gender** | **107** | **55.2%** | | **12** | **42.9%** | | **0.232** |
| **Body mass index (kg/m2)** | **23.8** | **(4.2)** | | **22.8** | **(3.9)** | | **0.252** |
| **Heart rate at baseline (beats per minute)** | **87.4** | **(17.2)** | | **90.7** | **(19.6)** | | **0.349** |
| **Systolic BP at baseline (mm Hg)** | **148.9** | **(31.1)** | | **141.8** | **(27.8)** | | **0.253** |
| **Diastolic BP at baseline (mm Hg)** | **75.6** | **(14.3)** | | **73.6** | **(13.1)** | | **0.472** |
| **Current/past smoker** | **49** | **25.3%** | | **4** | **14.2%** | | **0.275** |
| **Alcohol intake** | **62** | **31.9%** | | **7** | **25.0%** | | **0.678** |
| **Family history of premature CAD** | **2** | **1%** | | **0** | **0%** | | **1.000** |
| **History of hypertension** | **124** | **63.9%** | | **21** | **75.0%** | | **0.293** |
| **History of diabetes mellitus** | **133** | **68.6%** | | **17** | **60.7%** | | **0.398** |
| **History of insulin use** | **27** | **13.9%** | | **1** | **3.6%** | | **0.218** |
| **History of dyslipidemia** | **42** | **21.6%** | | **4** | **14.3%** | | **0.461** |
| **History of kidney disease** |  |  | |  |  | | **0.011** |
| **Normal kidney function** | **117** | **60.3%** | | **24** | **85.7%** | |  |
| **Chronic kidney disease** | **32** | **16.5%** | | **4** | **14.3%** | |  |
| **End-stage renal disease** | **45** | **23.2%** | | **0** | **0** | |  |
| **History of CAD** | **81** | **41.8%** | | **9** | **32.1%** | | **0.412** |
| **History of myocardial infarction** | **12** | **6.2%** | | **2** | **7.1%** | | **0.692** |
| **History of chronic heart failure** |  |  | |  |  | | **0.684** |
| **NYHA class I** | **8** | **4.1%** | | **2** | **7.1%** | |  |
| **NYHA class II** | **10** | **5.2%** | | **2** | **7.1%** | |  |
| **NYHA class III** | **12** | **6.2%** | | **3** | **10.7%** | |  |
| **NYHA class IV** | **5** | **2.6%** | | **0** | **0%** | |  |
| **History of carotid artery stenosis** | **3** | **1.5%** | | **0** | **0%** | | **1.000** |
| **History of ischemic stroke** | **27** | **13.9%** | | **8** | **28.6%** | | **0.056** |
| **History of any cancer** | **10** | **5.2%** | | **3** | **10.7%** | | **0.216** |
| **History of amputation** | **13** | **6.7%** | | **0** | **0%** | | **0.949** |
| **Above-knee amputation** | **6** | **3.1%** | | **0** | **0%** | |  |
| **Below-knee amputation** | **3** | **1.5%** | | **0** | **0%** | |  |
| **Forefoot amputation** | **4** | **2.1%** | | **0** | **0%** | |  |
| **Presented with acute ischemic limb** | **21** | **10.8%** | | **7** | **25.0%** | | **0.035** |
| **Rutherford classification** |  |  | |  |  | | **0.663** |
| **Class III** | **23** | **11.9%** | | **2** | **7.1%** | |  |
| **Class IV** | **45** | **23.2%** | | **9** | **32.1%** | |  |
| **Class V** | **114** | **58.8%** | | **16** | **57.1%** | |  |
| **Class VI** | **12** | **6.2%** | | **1** | **3.6%** | |  |
| **CHADS2 score** | **2.2** | **(1.2)** | | **2.9** | **(1.3)** | | **0.004** |
| **Laboratory data** |  |  | |  |  | |  |
| **Total cholesterol (mg/dl)** | **160** | **(47.0)** | | **148.0** | **(37.0)** | | **0.204** |
| **High-density lipoprotein cholesterol (mg/dl)** | **40.0** | **(16.0)** | | **42.0** | **(27.0)** | | **0.815** |
| **Low-density lipoprotein cholesterol (mg/dl)** | **95.0** | **(37.0)** | | **93.0** | **(30.0)** | | **0.902** |
| **Triglyceride (mg/dl)** | **158.0** | **(125.0)** | | **105.0** | **(67.0)** | | **0.033** |
| **Fasting glucose (mg/dl)** | **176.0** | **(99.0)** | | **177.0** | **(116.0)** | | **0.965** |
| **Glycosylated hemoglobin (%)** | **7.3** | **(1.9)** | | **7.9** | **(2.1)** | | **0.257** |
| **Creatinine (mg/dl)** | **3.7** | **(3.5)** | | **1.8** | **(1.1)** | | **<0.001** |
| **Creatinine clearance (ml/min)** | **34.1** | **(31.0)** | | **33.3** | **(19.4)** | | **0.852** |
| **Estimated glomerular filtration rate (ml/min/1.732)** | **41.6** | **(37.0)** | | **46.2** | **(28.7)** | | **0.448** |
| **Alanine transaminase (IU/L)** | **22.0** | **(19.0)** | | **30.0** | **(31.0)** | | **0.150** |
| **Uric acid (mg/dl)** | **5.7** | **(2.2)** | | **6.8** | **(2.9)** | | **0.022** |
| **White blood cell count 103/*µ*l** | **9645** | **(4970)** | | **8593** | **(4623)** | | **0.029** |
| **Neutrophil ratio (%)** | **70.5** | **(13.3)** | | **67.7** | **(17.4)** | | **0.330** |
| **Lymphocyte ratio (%)** | **17.1** | **(10.1)** | | **17.0** | **(8.4)** | | **0.969** |
| **NLR** | **7.9** | **(10.0)** | | **6.3** | **(6.4)** | | **0.421** |
| **Medication use at baseline** |  |  | |  |  | |  |
| **Aspirin** | **70** | **36.1%** | | **12** | **42.9%** | | **0.533** |
| **Cilostazol** | **93** | **47.9%** | | **15** | **53.6%** | | **0.687** |
| **Clopidogrel** | **57** | **29.4%** | | **4** | **14.3%** | | **0.115** |
| **Oral anti-coagulants** | **0** | **0%** | | **7** | **25.0%** | | **<0.001** |
| **Pentoxifylline** | **8** | **4.1%** | | **3** | **10.7%** | | **0.148** |
| **ACEI or ARB** | **9** | **4.6%** | | **2** | **7.1%** | | **0.634** |
| **Beta-blocker** | **33** | **17.0%** | | **6** | **21.4%** | | **0.596** |
| **Calcium channel blocker** | **39** | **20.1%** | | **9** | **32.1%** | | **0.149** |
| **Statin** | **42** | **21.6%** | | **2** | **7.1%** | | **0.080** |
| **Urate lowering therapy** | **3** | **1.5%** | | **2** | **7.1%** | | **0.121** |

**Values are expressed as numbers (standard deviation) or numbers and percentages.**

**Afib = atrial fibrillation; CAD = coronary artery disease; NYHA = New York Heart Association; BP = blood pressure; NLR = neutrophil-to-lymphocyte ratio; ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker**